Press Releases - WDM Group PR Network  

SEATTLE, Oct. 3, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today announced the formation of an exclusive, world-wide collaboration with Celgene Corporation (NASDAQ: CELG)...

MENLO PARK, Calif., Oct. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today that it is presenting two abstracts from its Phase 3 clinical trial, BREEZE 3, at this week's 23rd Annual Meeting of the North American Menopause Society (NAMS)...

WINSTON-SALEM, N.C., Oct. 3, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced  the pricing of a private placement of $15.0 million aggregate principal amount of Senior Secured Convertible Notes (the "Notes"), with certain investors, including...

MUMBAI, October 3, 2012 /PRNewswire/ -- New Flanged Contact Element Offers Greater Stability Volk Optical has redesigned its H-R Wide Field pan retinal lens with a new flanged contact element for greater stability. The new contact prevents patients from squeezing...

AUSTIN, Texas, Oct. 3, 2012 /PRNewswire/ -- dailyRx, Inc., a leading digital news publisher, announced today the top five health conditions and medications viewed on the dailyRx News Network during September 2012. dailyRx News is syndicated to consumers across...

WATSONVILLE, Calif., Oct. 3, 2012 /PRNewswire/ -- Nordic Naturals, leading manufacturer of omega-3 supplements, introduces Baby's DHA Vegetarian, made exclusively from microalgae, nature's original source of marine omega-3s. Baby's DHA Vegetarian provides essential omega nutrition without the use of fish....

LOS ANGELES, CA--(Marketwire - October 2, 2012) - Douglas, Isle of Man-based Odyssey Moon Ltd. and Israeli-based NSL Satellites Ltd., in partnership with NanoRacks LLC of the U.S., together will fly a number of educational microgravity experiments to the International...

Tim Dyer Chief Financial Officer Addex Therapeutics +41 22 884 15 61 PR(at)addextherapeutics.com

For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: Email Contact Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: Email Contact Follow us on Twitter @AblynxABLX M:Communications: Mary-Jane Elliott Amber Bielecka Claire Dickinson t: +44 207 920 2330 e: Email Contact

Contact:
Five Star Equities
Email Contact